
@article{ref1,
title="Detection of brain specific cardiolipins in plasma after experimental pediatric head injury",
journal="Experimental neurology",
year="2019",
author="Anthonymuthu, Tamil S. and Kenny, Elizabeth M. and Hier, Zachary E. and Clark, Robert S. B. and Kochanek, Patrick M. and Kagan, Valerian E. and Bayir, Hulya",
volume="316",
number="",
pages="63-73",
abstract="Cardiolipin (CL) is a mitochondria-specific phospholipid that is central to maintenance and regulation of mitochondrial bioenergetic and metabolic functions. CL molecular species display great tissue variation with brain exhibiting a distinct, highly diverse CL population. We recently showed that the appearance of unique brain-type CLs in plasma could serve as a brain-specific marker of mitochondrial/tissue injury in patients after cardiac arrest. Mitochondrial dysfunction has been increasingly implicated as a critical mechanism underlying the pathogenesis of traumatic brain injury (TBI). Therefore, we hypothesized that unique, brain specific CL species from the injured brain are released to the peripheral circulation after TBI. To test this hypothesis, we performed a high-resolution mass spectrometry based phospholipidomics analysis of post-natal day (PND)-17 rat brain and plasma after controlled cortical impact. We found a time dependent increase in plasma CLs after TBI including the aforementioned brain-specific CL species early after injury, whereas CLs were significantly decreased in the injured brain. Compositional and quantitative correlational analysis suggested a possible release of CL into the systemic circulation following TBI. The identification of brain-type CLs in systemic circulation may indicate underlying mitochondrial dysfunction/loss after TBI. They may have potential as pharmacodynamics response biomarkers for targeted therapies.<br><br>Copyright © 2019. Published by Elsevier Inc.<p /> <p>Language: en</p>",
language="en",
issn="0014-4886",
doi="10.1016/j.expneurol.2019.04.007",
url="http://dx.doi.org/10.1016/j.expneurol.2019.04.007"
}